RT Journal Article
SR Electronic
T1 mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020-December 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.14.21267809
DO 10.1101/2021.12.14.21267809
A1 McLean, Huong Q
A1 McClure, David L
A1 King, Jennifer P
A1 Meece, Jennifer K
A1 Pattinson, David
A1 Neumann, Gabriele
A1 Kawaoka, Yoshihiro
A1 Rolfes, Melissa A
A1 Belongia, Edward A
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.12.14.21267809.abstract
AB Reduced COVID-19 vaccine effectiveness (VE) has been observed with increasing predominance of the Delta variant. In a prospective rural community cohort of 1265 participants, VE against symptomatic and asymptomatic SARS-CoV-2 infection was 56% for mRNA COVID-19 vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the US Centers for Disease Control and Prevention (Grant number 75D30120C09259).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at Marshfield Clinic Research Institute reviewed and gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in the present study may be available upon reasonable request to the authors.